EcoDrugPlus

Phosphodiesterase 3b

Ensembl ID : ENSPSNG00000005620
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSPSNG00000020907
Gene Symbol: PDE4A
3 Cross references
275 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSPSNG00000003736
Gene Symbol: PDE4B
3 Cross references
292 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSPSNG00000003220
Gene Symbol: PDE4C
1 Cross references
269 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSPSNG00000006614
Gene Symbol: PDE4D
3 Cross references
244 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSPSNG00000000435
Gene Symbol: PDE5A
3 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSPSNG00000016390
Gene Symbol: PDE7A
3 Cross references
253 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSPSNG00000018778
Gene Symbol: PDE7B
3 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSPSNG00000005243
Gene Symbol: PDE9A
1 Cross references
280 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSPSNG00000008942
Gene Symbol: PIK3R1
3 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSPSNG00000003482
Gene Symbol: PIK3R2
3 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSPSNG00000006562
Gene Symbol: PIK3R3
3 Cross references
274 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).